In addition, cohort and treatment definitions were subject to misattribution bias (eg, programmed cell death 1 ligand 1 status is unknown for patients with lung cancer) that may overestimate or underestimate receipt of novel therapy but would not be expected to bias results in the direction of either OCM or non-OCM participation. The gene discussed is CD274; the disease is lung carcinoma.